These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31188803)

  • 1. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
    Kantarjian HM
    Clin Adv Hematol Oncol; 2019 May; 17(5):268-270. PubMed ID: 31188803
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Rausch CR; Jabbour EJ; Kantarjian HM; Kadia TM
    Cancer; 2020 Mar; 126(6):1152-1160. PubMed ID: 31794095
    [No Abstract]   [Full Text] [Related]  

  • 5. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
    Kantarjian H; Jabbour E
    Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
    Paul S; Rausch CR; Kantarjian H; Jabbour EJ
    Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
    Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
    Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytarabine induced noncardiogenic pulmonary edema in a case of acute lymphoblastic leukemia.
    Yegin ZA; Aki S; Sucak G; Yagci M
    Int J Lab Hematol; 2007 Dec; 29(6):482-3. PubMed ID: 17988309
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
    Benton CB; Thomas DA; Yang H; Ravandi F; Rytting M; O'Brien S; Franklin AR; Borthakur G; Dara S; Kwari M; Pierce SR; Jabbour E; Kantarjian H; Garcia-Manero G
    Br J Haematol; 2014 Nov; 167(3):356-65. PubMed ID: 25066676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
    Ponvilawan B; Vittayawacharin P; Tunsing P; Owattanapanich W
    Technol Cancer Res Treat; 2021; 20():15330338211037434. PubMed ID: 34350787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
    Chamberlain MC; Glantz MJ
    Blood; 2007 Sep; 110(5):1698; author reply 1698-9. PubMed ID: 17712051
    [No Abstract]   [Full Text] [Related]  

  • 14. [Intrathecal chemotherapy in acute lymphoblastic leukemia. Prospective evaluation of toxicity using a combination employed in Mexico].
    Gómez-Almaguer D; Almaguer-Gaona C; Mora-Brondo P; González-Llano O; Marfil-Rivera J; Villarreal G
    Rev Invest Clin; 1988; 40(2):129-33. PubMed ID: 3175366
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Chan TSY; Kwong YL
    Ann Hematol; 2018 Feb; 97(2):371-373. PubMed ID: 29032509
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
    Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
    Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
    Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.